bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

pathway activation upon BRAFi resistance
Table S3 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Authors: Guarneri Valentina , Dieci Maria Vittoria , Bisagni Giancarlo , Brandes Alba A. , Frassoldati Antonio , Cavanna Luigi , Musolino Antonino , Giotta Francesco , Rimanti Anita , Garrone Ornella , Bertone Elena , Cagossi Katia , Nanni Oriana , Piacentini Federico , Orvieto Enrico , Griguolo Gaia , Curtarello Matteo , Urso Loredana , Paré Laia , Chic Nuria , D'Amico Roberto , Prat Aleix , Conte Pierfranco
Published: April 2023

HER2-enriched molecular subtype: patients' characteristics according to PIK3CA gene status.
Supplementary Materials and Methods from OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models
Authors: Fabre Myriam , Ferrer Cristina , Domínguez-Hormaetxe Saioa , Bockorny Bruno , Murias Laura , Seifert Oliver , Eisler Stephan A. , Kontermann Roland E. , Pfizenmaier Klaus , Lee So Young , Vivanco María dM. , López-Casas Pedro P. , Perea Sofia , Abbas Muhammad , Richter Wolfgang , Simon Laureano , Hidalgo Manuel
Published: April 2023

Additional Materials and Methods information not included in the article text, and detailed description of the patient tumors from which xenograft models have been derived from
Figure S5 from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Authors: Glisson Bonnie S. , Leidner Rom S. , Ferris Robert L. , Powderly John , Rizvi Naiyer A. , Keam Bhumsuk , Schneider Reva , Goel Sanjay , Ohr James P. , Burton Jennifer , Zheng Yanan , Eck Steven , Gribbin Matthew , Streicher Katie , Townsley Danielle M. , Patel Sandip Pravin
Published: April 2023

Figure S5: Dual MoA of MEDI0562
FigureS4 from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

RNA-Seq analysis in HDMB03 and DAOY upon treatment.
Figure S2 from Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Authors: Mei Qian , Zhang Wenying , Liu Yang , Yang Qingming , Rasko John E.J. , Nie Jing , Liu Jiejie , Li Xiang , Dong Liang , Chen Meixia , Zhang Yan , Shi Lu , Wu Huitao , Han Weidong
Published: April 2023

CT or PET-CT scans of all evaluated patients
Figure S1 from Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis
Authors: Indraccolo Stefano , De Salvo Gian Luca , Verza Martina , Caccese Mario , Esposito Giovanni , Piga Ilaria , Del Bianco Paola , Pizzi Marco , Gardiman Marina Paola , Eoli Marica , Rudà Roberta , Brandes Alba Ariela , Ibrahim Toni , Rizzato Simona , Lolli Ivan , Zagonel Vittorina , Lombardi Giuseppe
Published: April 2023

Immunohistochemical staining of pACC in three representative GBM samples
Supplementary Table S9 from Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA
Authors: Zeng Shuxiong , Ying Yidie , Xing Naidong , Wang Baiyun , Qian Ziliang , Zhou Zunlin , Zhang Zhensheng , Xu Weidong , Wang Huiqing , Dai Lihe , Gao Li , Zhou Tie , Ji Jiatao , Xu Chuanliang
Published: April 2023

Comparison of UroCAD and urine cytology tests in the validation cohort.
Supplementary Figure S2 from Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA
Authors: Zeng Shuxiong , Ying Yidie , Xing Naidong , Wang Baiyun , Qian Ziliang , Zhou Zunlin , Zhang Zhensheng , Xu Weidong , Wang Huiqing , Dai Lihe , Gao Li , Zhou Tie , Ji Jiatao , Xu Chuanliang
Published: April 2023

Comparison of UroCAD results of urine samples stored for 2 hours and 72 hours.
Supplementary Appendix from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer
Authors: Bardia Aditya , Modi Shanu , Oliveira Mafalda , Cortes Javier , Campone Mario , Ma Brigette , Dirix Luc , Weise Amy , Hewes Becker , Diaz-Padilla Ivan , Han Yu , Deshpande Priya , Samant Tanay S. , Lorenc Karen Rodriguez , He Wei , Su Fei , Chavez-MacGregor Mariana
Published: April 2023

Supplementary Appendix
Table S3 from Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study
Authors: Bagley Stephen J. , Nabavizadeh S. Ali , Mays Jazmine J. , Till Jacob E. , Ware Jeffrey B. , Levy Scott , Sarchiapone Whitney , Hussain Jasmin , Prior Timothy , Guiry Samantha , Christensen Theresa , Yee Stephanie S. , Nasrallah MacLean P. , Morrissette Jennifer J.D. , Binder Zev A. , O'Rourke Donald M. , Cucchiara Andrew J. , Brem Steven , Desai Arati S. , Carpenter Erica L.
Published: April 2023

Circulating tumor DNA next-generation sequencing gene coverage (74 genes)
Table S1 from Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study
Authors: Bagley Stephen J. , Nabavizadeh S. Ali , Mays Jazmine J. , Till Jacob E. , Ware Jeffrey B. , Levy Scott , Sarchiapone Whitney , Hussain Jasmin , Prior Timothy , Guiry Samantha , Christensen Theresa , Yee Stephanie S. , Nasrallah MacLean P. , Morrissette Jennifer J.D. , Binder Zev A. , O'Rourke Donald M. , Cucchiara Andrew J. , Brem Steven , Desai Arati S. , Carpenter Erica L.
Published: April 2023

Tissue next-generation sequencing gene coverage (152 genes)
Supplementary Figure 7 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplemental Figure 7. Bioluminescent imaging.
Supplementary Table S3 from Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Authors: Kang Yoon-Koo , Bang Yung-Jue , Kondo Shunsuke , Chung Hyun Cheol , Muro Kei , Dussault Isabelle , Helwig Christoph , Osada Motonobu , Doi Toshihiko
Published: April 2023

Supplementary Table S3 shows inconsistencies between confirmed best overall responses.
Supplementary Table S2 from Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Authors: Kang Yoon-Koo , Bang Yung-Jue , Kondo Shunsuke , Chung Hyun Cheol , Muro Kei , Dussault Isabelle , Helwig Christoph , Osada Motonobu , Doi Toshihiko
Published: April 2023

Supplementary Table S2 shows the study inclusion and exclusion criteria.
Supplementary Table S1 from Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Authors: Kang Yoon-Koo , Bang Yung-Jue , Kondo Shunsuke , Chung Hyun Cheol , Muro Kei , Dussault Isabelle , Helwig Christoph , Osada Motonobu , Doi Toshihiko
Published: April 2023

Supplementary Table S1 shows the system for mapping tumor histology from the Japanese or World Health Organization classification systems to the Lauren classification system.
Supplementary Figure 5 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplemental Figure 5. Confirmation of gut microbiota depletion.
Supplementary Figure S2 from Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Authors: Kang Yoon-Koo , Bang Yung-Jue , Kondo Shunsuke , Chung Hyun Cheol , Muro Kei , Dussault Isabelle , Helwig Christoph , Osada Motonobu , Doi Toshihiko
Published: April 2023

Supplementary Figure S2 shows the Kaplan-Meier plots of investigator-assessed progression-free survival.
Supplementary Information from The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Authors: Jordan Kimberly R. , Sikora Matthew J. , Slansky Jill E. , Minic Angela , Richer Jennifer K. , Moroney Marisa R. , Hu Junxiao , Wolsky Rebecca J. , Watson Zachary L. , Yamamoto Tomomi M. , Costello James C. , Clauset Aaron , Behbakht Kian , Kumar T. Rajendra , Bitler Benjamin G.
Published: April 2023

Detailed Clinical History. Supplemental figure legend Supplemental table legends.
TMK1_3 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Authors: Galletti Giuseppe , Zhang Chao , Gjyrezi Ada , Cleveland Kyle , Zhang Jiaren , Powell Sarah , Thakkar Prashant V. , Betel Doron , Shah Manish A. , Giannakakou Paraskevi
Published: April 2023

TMK1_3 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Table S4 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Table S4. Concordance of pre- vs. post-treatment PD-L1 status among patients with and without exposure to specific therapies.
TMK1_1 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Authors: Galletti Giuseppe , Zhang Chao , Gjyrezi Ada , Cleveland Kyle , Zhang Jiaren , Powell Sarah , Thakkar Prashant V. , Betel Doron , Shah Manish A. , Giannakakou Paraskevi
Published: April 2023

TMK1_1 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Figure S6 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Figure S6. Overall survival stratified by TMB.
Supplementary Data from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Authors: Galletti Giuseppe , Zhang Chao , Gjyrezi Ada , Cleveland Kyle , Zhang Jiaren , Powell Sarah , Thakkar Prashant V. , Betel Doron , Shah Manish A. , Giannakakou Paraskevi
Published: April 2023

Supplementary data
HS746T_3 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Authors: Galletti Giuseppe , Zhang Chao , Gjyrezi Ada , Cleveland Kyle , Zhang Jiaren , Powell Sarah , Thakkar Prashant V. , Betel Doron , Shah Manish A. , Giannakakou Paraskevi
Published: April 2023

HS746T_3 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
HS746T_1 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Authors: Galletti Giuseppe , Zhang Chao , Gjyrezi Ada , Cleveland Kyle , Zhang Jiaren , Powell Sarah , Thakkar Prashant V. , Betel Doron , Shah Manish A. , Giannakakou Paraskevi
Published: April 2023

HS746T_1 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Supplementary Data from Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Authors: Strosberg Jonathan , Mizuno Nobumasa , Doi Toshihiko , Grande Enrique , Delord Jean-Pierre , Shapira-Frommer Ronnie , Bergsland Emily , Shah Manisha , Fakih Marwan , Takahashi Shunji , Piha-Paul Sarina A. , O'Neil Bert , Thomas Sajeve , Lolkema Martijn P. , Chen Menghui , Ibrahim Nageatte , Norwood Kevin , Hadoux Julien
Published: April 2023

Study Protocol.
Supplementary Data 2 from CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy
Authors: Xiong Zhengming , Ampudia Mesias Elisabet , Pluhar G. Elizabeth , Rathe Susan K. , Largaespada David A. , Sham Yuk Y. , Moertel Christopher L. , Olin Michael R.
Published: April 2023

CD200R1 and PD-1 expression.
Figure S1 from Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Authors: Strosberg Jonathan , Mizuno Nobumasa , Doi Toshihiko , Grande Enrique , Delord Jean-Pierre , Shapira-Frommer Ronnie , Bergsland Emily , Shah Manisha , Fakih Marwan , Takahashi Shunji , Piha-Paul Sarina A. , O'Neil Bert , Thomas Sajeve , Lolkema Martijn P. , Chen Menghui , Ibrahim Nageatte , Norwood Kevin , Hadoux Julien
Published: April 2023

Figure S1 shows the participant enrollment and treatment disposition.
Supplementary Table from Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck
Authors: Shin Dong M. , Nannapaneni Sreenivas , Patel Mihir R. , Shi Qiuying , Liu Yuan , Chen Zhengjia , Chen Amy Y. , El-Deiry Mark W. , Beitler Jonathan J. , Steuer Conor E. , Roser Steven M. , Klein Adam M. , Owonikoko Taofeek K. , Ramalingam Suresh S. , Khuri Fadlo R. , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

Supplementary Table S1: Univariate Association with Tissue Response
Supplementary Data from Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Authors: Ciruelos Eva , Villagrasa Patricia , Pascual Tomás , Oliveira Mafalda , Pernas Sonia , Paré Laia , Escrivá-de-Romaní Santiago , Manso Luis , Adamo Barbara , Martínez Eduardo , Cortés Javier , Vazquez Silvia , Perelló Antonia , Garau Isabel , Melé Mireia , Martínez Noelia , Montaño Alvaro , Bermejo Begoña , Morales Serafin , Echarri María J. , Vega Estela , González-Farré Blanca , Martínez Débora , Galván Patricia , Canes Jordi , Nuciforo Paolo , Gonzalez Xavier , Prat Aleix
Published: April 2023

Supplementary Data
Sppelementary Figures from Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck
Authors: Shin Dong M. , Nannapaneni Sreenivas , Patel Mihir R. , Shi Qiuying , Liu Yuan , Chen Zhengjia , Chen Amy Y. , El-Deiry Mark W. , Beitler Jonathan J. , Steuer Conor E. , Roser Steven M. , Klein Adam M. , Owonikoko Taofeek K. , Ramalingam Suresh S. , Khuri Fadlo R. , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

Supplementary Figures S1A & S1B.
Supplementary Data from Anti–PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells
Authors: Rao Ganesh , Latha Khatri , Ott Martina , Sabbagh Aria , Marisetty Anantha , Ling Xiaoyang , Zamler Daniel , Doucette Tiffany A. , Yang Yuhui , Kong Ling-Yuan , Wei Jun , Fuller Gregory N. , Benavides Fernando , Sonabend Adam M. , Long James , Li Shulin , Curran Michael , Heimberger Amy B.
Published: April 2023

Supplementary Figures 1-7
Supplementary Data from Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer
Authors: Gerber David E. , Putnam William C. , Fattah Farjana J. , Kernstine Kemp H. , Brekken Rolf A. , Pedrosa Ivan , Skelton Rachael , Saltarski Jessica M. , Lenkinski Robert E. , Leff Richard D. , Ahn Chul , Padmanabhan Chyndhri , Chembukar Vaidehi , Kasiri Sahba , Kallem Raja Reddy , Subramaniyan Indhumathy , Yuan Qing , Do Quyen N. , Xi Yin , Reznik Scott I. , Pelosof Lorraine , Faubert Brandon , DeBerardinis Ralph J. , Kim James
Published: April 2023

Supplementary
Supplementary Tables S1-S4 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Table S1-Post-PET biodistribution data of i.v.- and i.p.-administered 64Cu-RaftRGD in IGR-OV1-OCPM mice; Table S2-Biodistribution data of i.p.-administered 64Cu-RaftRGD; Table S3-Inverse regression equations; and Table S4-Estimation of human absorbed doses.
Supplementary fig 9 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 9: Changes in sTILs after NAC do not correspond to an observed change in T cell clonality.
Supplementary fig 7 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 7: Changes in immunologic signatures in response to NAC are not associated with outcome in non-TNBC tumors with residual disease.
Supplementary fig 6 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 6: Neither time of sample nor institution drive significant gene expression changes.
Figure S5 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Spatial relationship of intratumoral Cy5.5-RaftRGD to the tumor microenvironment (detailed images for s.c. xenografts)
Supplementary fig 4 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 4: sTILs are not prognostic in ER+ or HER2+ disease.
Supplementary fig 3 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 3: The prognostic value of sTILs is primarily confined to the post-NAC specimen in TNBC patients with residual disease.
Figure S3 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

ITD of 64CuCl2 after i.v. and i.p. injection
Supplementary fig 16 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 16: 8 gene score is predominately expressed by CD8+ T cells and NK cells in both patients.
Supplementary fig 13 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 13: Purity-of-sort analysis.
Supplementary fig 12 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 12: TCRβ repertoires in the post-NAC residual disease or tumor scar are most like PD-1HI CD8+ peripheral repertoires.
Figure S11 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Intertumoral heterogeneity of 64Cu-RaftRGD uptake
Figure S10 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Pharmacokinetics of i.p.-administered 64Cu-RaftRGD in ascites of IGR-OV1-OCPM mice
Supplementary Materials from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Materials
Supplementary Figure S8 from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Figure S8
Supplementary Table S1 from Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer
Authors: Datta Jashodeep , Smith J. Joshua , Chatila Walid K. , McAuliffe John C. , Kandoth Cyriac , Vakiani Efsevia , Frankel Timothy L. , Ganesh Karuna , Wasserman Isaac , Lipsyc-Sharf Marla , Guillem Jose , Nash Garrett M. , Paty Philip B. , Weiser Martin R. , Saltz Leonard B. , Berger Michael F. , Jarnagin William R. , Balachandran Vinod , Kingham T. Peter , Kemeny Nancy E. , Cercek Andrea , Garcia-Aguilar Julio , Taylor Barry S. , Viale Agnes , Yaeger Rona , Solit David B. , Schultz Nikolaus , D'Angelica Michael I.
Published: April 2023

Genomic and clinical information of MSKCC validation cohort (n=935) with corresponding data dictionary
Supplementary Material from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma
Authors: Accomando William P. , Rao Aliz R. , Hogan Daniel J. , Newman Aaron M. , Nakao Aki , Alizadeh Ash A. , Diehn Maximilian , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Supplementary Figures S1 to S9 and Supplementary Table S1.
Supplementary Data from Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Authors: Carlino Matteo S. , Menzies Alexander M. , Atkinson Victoria , Cebon Jonathan S. , Jameson Michael B. , Fitzharris Bernard M. , McNeil Catriona M. , Hill Andrew G. , Ribas Antoni , Atkins Michael B. , Thompson John A. , Hwu Wen-Jen , Hodi F. Stephen , Guminski Alexander D. , Kefford Richard , Wu Haiyan , Ibrahim Nageatte , Homet Moreno Blanca , Long Georgina V.
Published: April 2023

Supplementary Materials
Figure S1 from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Authors: Basler Lucas , Gabryś Hubert S. , Hogan Sabrina A. , Pavic Matea , Bogowicz Marta , Vuong Diem , Tanadini-Lang Stephanie , Förster Robert , Kudura Ken , Huellner Martin W. , Dummer Reinhard , Guckenberger Matthias , Levesque Mitchell P.
Published: April 2023

Feature weights of the multivariate models for PP-prediction.
Figure S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Authors: Wei Hui , Wang Ying , Gale Robert Peter , Lin Dong , Zhou Chunlin , Liu Bingcheng , Qiu Shaowei , Gu Runxia , Li Yan , Zhao Xingli , Wei Shuning , Gong Benfa , Liu Kaiqi , Gong Xiaoyuan , Liu Yuntao , Zhang Guangji , Song Zhen , Wang Yang , Li Wei , Mi Yingchang , Wang Jianxiang
Published: April 2023

Figure S5. Outcomes after consolidation when censoring transplant recipients
Figure S4 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Authors: Wei Hui , Wang Ying , Gale Robert Peter , Lin Dong , Zhou Chunlin , Liu Bingcheng , Qiu Shaowei , Gu Runxia , Li Yan , Zhao Xingli , Wei Shuning , Gong Benfa , Liu Kaiqi , Gong Xiaoyuan , Liu Yuntao , Zhang Guangji , Song Zhen , Wang Yang , Li Wei , Mi Yingchang , Wang Jianxiang
Published: April 2023

Figure S4. Outcomes of cytogenetic risk subgroup analysis
Supplementary Figure 9 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Authors: Ryan Meagan B. , Fece de la Cruz Ferran , Phat Sarah , Myers David T. , Wong Edmond , Shahzade Heather A. , Hong Catriona B. , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S9. Combined SHP2 and KRASG12C inhibition improves efficacy in vivo.
Supplementary Fig 3 from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
Authors: Paradis Justine S. , Acosta Monica , Saddawi-Konefka Robert , Kishore Ayush , Lubrano Simone , Gomes Frederico , Arang Nadia , Tiago Manoela , Coma Silvia , Wu Xingyu , Ford Kyle , Day Chi-Ping , Merlino Glenn , Mali Prashant , Pachter Jonathan A. , Sato Takami , Aplin Andrew E. , Gutkind J. Silvio
Published: April 2023

Supplementary figure 3. MEKi/FAKi combination reduces UM cells growth in xenograft tumor models with limited toxicity.
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Table S1, Table S2, Table S3 from DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors
Authors: Chung Jin-Sung , Ramani Vijay , Kobayashi Masato , Fattah Farjana , Popat Vinita , Zhang Song , Cruz Ponciano D. , Gerber David E. , Ariizumi Kiyoshi
Published: April 2023

Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Table S1, Table S2, Table S3
Supplementary Figure Legend from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Authors: Liu Chen , Lu Hengyu , Wang Hongyun , Loo Alice , Zhang Xiamei , Yang Guizhi , Kowal Colleen , Delach Scott , Wang Ye , Goldoni Silvia , Hastings William D. , Wong Karrie , Gao Hui , Meyer Matthew J. , Moody Susan E. , LaMarche Matthew J. , Engelman Jeffrey A. , Williams Juliet A. , Hammerman Peter S. , Abrams Tinya J. , Mohseni Morvarid , Caponigro Giordano , Hao Huai-Xiang
Published: April 2023

Supplementary Figure Legend
Supplementary Table-12 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

List of genes included in the colorectal cancer CMS classifier
Supplementary Table-10 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Summary of sample-wise FF/FFPE Spearman Correlations. Summary of sample-wise paired FF/FFPE correlations across 472 CMS genes for batch 1 containing CRCSC samples (top), batch 2 containing non-CRCSC samples (middle), and all samples (bottom).
Supplementary Figure 16 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Affect of mutation abundance in tumor biopsy on MRD detection in early stage breast cancer cohort. (A) Allele fraction histogram of all tracked mutaions and whether they were detected or not. (B) Cancer cell fraction distribution of all tracked mutations and whether they were detected or not.
Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

MRD testing results in early stage breast cancer cohort. (A) Detection limits versus the number of SNVs tracked for each cfDNA sample. (B) Comparison of fingerprint size distributions between patients that were MRD+ at any time point and those that were always MRD-, split by distant recurrence status. The Mann-Whitney U test was used to determine whether MRD+ patients tracked significantly more mutations than MRD- patients. (C) Tumor fractions for MRD+ samples from patients with distant recurrence split by the minimum fingerprint size required to still detect MRD.
Supplementary Figure-4 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Classification Confidence of Affymetrix Validation Samples vs. Classification Accuracy of 472-gene wSVM clas-sifier: Distribution of classification confidence (ï�¡i) across 713 validation samples (top), and classification accura-cy (1=correct, 0=incorrect) as a function of classification confidence (ï�¡i), with fitted loess curve and 95% confidence interval.
Supplementary Figure 10 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Reproducibility of patient specific MRD tests. Consensus molecule overlap assessed for both replicate captures and replicate sequencing.
Table S3 from Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia
Authors: Tang Lu , Wu Jianghua , Li Cheng-Gong , Jiang Hui-Wen , Xu Min , Du Mengyi , Yin Zhinan , Mei Heng , Hu Yu
Published: April 2023

Table S3 shows the correlations between clinical parameters and immune signatures.
Supplementary Figure 2 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Authors: Thorat Mangesh A. , Levey Pauline M. , Jones J. Louise , Pinder Sarah E. , Bundred Nigel J. , Fentiman Ian S. , Cuzick Jack
Published: April 2023

Supplementary Figure 2 - Multi-clonality in ER expression in DCIS.
Supplementary Data from Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy
Authors: Walker Zachary J. , Idler Beau M. , Davis Lorraine N. , Stevens Brett M. , VanWyngarden Michael J. , Ohlstrom Denis , Bearrows Shelby C. , Hammes Andrew , Smith Clayton A. , Jordan Craig T. , Mark Tomer M. , Forsberg Peter A. , Sherbenou Daniel W.
Published: April 2023

Supplemental Data
Supplementary Table 7 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

The table shows maximum acute GVHD organ stage and overall grade observed through day +100 after transplant on the PAC/SIR/TAC phase I trial.
Supplementary Table 6 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

The table shows the pharmacokinetic analysis of pacritinib concentration over time.
Supplementary Table 5 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

The table shows pacritinib adherence during treatment period according to dose level on the PAC/SIR/TAC phase I trial.
Supplementary Table 4 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

The table shows donor chimerism in unsorted bone marrow, and peripheral blood CD3 and CD33 populations from patients treated on the PAC/SIR/TAC phase I trial.
Supplementary Table S3 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Authors: Demetri George D. , Luke Jason J. , Hollebecque Antoine , Powderly John D. , Spira Alexander I. , Subbiah Vivek , Naumovski Louie , Chen Chris , Fang Hua , Lai Dominic W. , Yue Huibin , Polepally Akshanth R. , Purcell James W. , Robinson Randy , Sharma Padmanee , Allison James P. , Tolcher Anthony , Villalobos Victor M.
Published: April 2023

Supplementary Table S3 shows patient demographics and baseline characteristics
Supplementary Table S2 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Authors: Demetri George D. , Luke Jason J. , Hollebecque Antoine , Powderly John D. , Spira Alexander I. , Subbiah Vivek , Naumovski Louie , Chen Chris , Fang Hua , Lai Dominic W. , Yue Huibin , Polepally Akshanth R. , Purcell James W. , Robinson Randy , Sharma Padmanee , Allison James P. , Tolcher Anthony , Villalobos Victor M.
Published: April 2023

Supplementary Table S2 shows LRRC15 IHC expression in tumor and stroma of patients with sarcoma treated ABBV-085 monotherapy at 3.6 or 4.2 mg/kg
Supplementary Table 2 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

The table shows donor/recipient CMV serostatus.
Supplementary Figure S2 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Authors: Demetri George D. , Luke Jason J. , Hollebecque Antoine , Powderly John D. , Spira Alexander I. , Subbiah Vivek , Naumovski Louie , Chen Chris , Fang Hua , Lai Dominic W. , Yue Huibin , Polepally Akshanth R. , Purcell James W. , Robinson Randy , Sharma Padmanee , Allison James P. , Tolcher Anthony , Villalobos Victor M.
Published: April 2023

Supplementary Figure S2 shows LRRC15 RNA data from NanoString and clinical response in nonresponder (n=19) and responder (n=5) patients with sarcoma
Extended Methods from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

Extended Methods including information and details regarding flow cytometry, cell lines, allogeneic mixed leukocyte reactions, Treg Suppression Assays, Xenogeneic GVHD modeling, and key reagents.
Supplementary table 4 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Authors: Scott Aaron T. , Weitz Michelle , Breheny Patrick J. , Ear Po Hien , Darbro Benjamin , Brown Bart J. , Braun Terry A. , Li Guiying , Umesalma Shaikamjad , Kaemmer Courtney A. , Maharjan Chandra K. , Quelle Dawn E. , Bellizzi Andrew M. , Chandrasekharan Chandrikha , Dillon Joseph S. , O'Dorisio Thomas M. , Howe James R.
Published: April 2023

Supplementary table 4
Supplementary Data 8 from Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma
Authors: Barwick Benjamin G. , Gupta Vikas A. , Matulis Shannon M. , Patton Jonathan C. , Powell Doris R. , Gu Yanyan , Jaye David L. , Conneely Karen N. , Lin Yin C. , Hofmeister Craig C. , Nooka Ajay K. , Keats Jonathan J. , Lonial Sagar , Vertino Paula M. , Boise Lawrence H.
Published: April 2023

ATAC-seq data for Emory patients.
Supplementary Data 7 from Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma
Authors: Barwick Benjamin G. , Gupta Vikas A. , Matulis Shannon M. , Patton Jonathan C. , Powell Doris R. , Gu Yanyan , Jaye David L. , Conneely Karen N. , Lin Yin C. , Hofmeister Craig C. , Nooka Ajay K. , Keats Jonathan J. , Lonial Sagar , Vertino Paula M. , Boise Lawrence H.
Published: April 2023

RNA-seq data for Emory patients.
Supplementary Data from The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Authors: Kendsersky Nathan M. , Lindsay Jarrett , Kolb E. Anders , Smith Malcolm A. , Teicher Beverly A. , Erickson Stephen W. , Earley Eric J. , Mosse Yael P. , Martinez Daniel , Pogoriler Jennifer , Krytska Kateryna , Patel Khushbu , Groff David , Tsang Matthew , Ghilu Samson , Wang Yifei , Seaman Steven , Feng Yang , Croix Brad St. , Gorlick Richard , Kurmasheva Raushan , Houghton Peter J. , Maris John M.
Published: April 2023

Supplemental Tables 1-2 and Supplemental Figures 1-10